Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma von George, S. L., Parmar, V., Lorenzi, F., Marshall, L. V., Jamin, Y., Poon, E., Angelini, P., Chesler, L.

Volltext

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN von Guan, J, Tucker, E R, Wan, H, Chand, D, Danielson, L S, Ruuth, K, El Wakil, A, Witek, B, Jamin, Y, Umapathy, G, Robinson, S P, Johnson, T W, Smeal, T, Martinsson, T, Chesler, L, Palmer, R H, Hallberg, B

Volltext

Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells von Sbirkov, Y, Schenk, T, Kwok, C, Stengel, S, Brown, R, Brown, G, Chesler, L, Zelent, A, Fuchter, M J, Petrie, K

Volltext

SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma von Carreno, G, Boult, J K R, Apps, J, Gonzalez-Meljem, J M, Haston, S, Guiho, R, Stache, C, Danielson, L S, Koers, A, Smith, L M, Virasami, A, Panousopoulos, L, Buchfelder, M, Jacques, T S, Chesler, L, Robinson, S P, Martinez-Barbera, J P

Volltext

Lactate and choline metabolites are potential biomarkers for monitoring response to mTOR pathway inhibitors in combination with the ALK inhibitor crizotinib in ALK-mutated neurobla... von Al-Saffar, N.M.S, Jackson, L.E, Sidhu, J, Chesler, L, Leach, M.O

Volltext

Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats von Volpert, O V, Ward, W F, Lingen, M W, Chesler, L, Solt, D B, Johnson, M D, Molteni, A, Polverini, P J, Bouck, N P

Volltext

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) von Bellini, Angela, Poetschger, Ulrike, Bernard, Virginie, Lapouble, Eve, Baulande, Sylvain, Ambros, Peter F., Auger, Nathalie, Beiske, Klaus, Bernkopf, Marie, Betts, David R., Bhalshankar, Jaydutt, Bown, Nick, de Preter, Katleen, Clement, Nathalie, Combaret, Valerie, de Mora, Jaime Font, George, Sally L., Jimenez, Irene, Jeison, Marta, Marques, Barbara, Martinsson, Tommy, Mazzocco, Katia, Morini, Martina, Muehlethaler-Mottet, Annick, Noguera, Rosa, Pierron, Gaelle, Rossing, Maria, Taschner-Mandl, Sabine, Van Roy, Nadine, Vicha, Ales, Chesler, Louis, Balwierz, Walentyna, Castel, Victoria, Elliott, Martin, Kogner, Per, Laureys, Genevieve, Luksch, Roberto, Malis, Josef, Popovic-Beck, Maja, Ash, Shifra, Delattre, Olivier, Valteau-Couanet, Dominique, Tweddle, Deborah A., Ladenstein, Ruth, Schleiermacher, Gudrun

Volltext

A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations von George, Sally L., Izquierdo, Elisa, Campbell, James, Koutroumanidou, Eleni, Proszek, Paula, Jamal, Sabri, Hughes, Deborah, Yuan, Lina, Marshall, Lynley V., Carceller, Fernando, Chisholm, Julia C., Vaidya, Sucheta, Mandeville, Henry, Angelini, Paola, Wasti, Ajla, Bexelius, Tomas, Thway, Khin, Gatz, Susanne A., Clarke, Matthew, Al-Lazikani, Bissan, Barone, Giuseppe, Anderson, John, Tweddle, Deborah A., Gonzalez, David, Walker, Brian A., Barton, Jack, Depani, Sarita, Eze, Jessica, Ahmed, Saira W., Moreno, Lucas, Pearson, Andrew, Shipley, Janet, Jones, Chris, Hargrave, Darren, Jacques, Thomas S., Hubank, Michael, Chesler, Louis

Volltext

716TiP DETERMINE: A pioneering UK precision medicine trial for rare cancers von Middleton, G., Marshall, L., Billingham, L., Duffus, K.D., Greystoke, A., Carter, L., Forster, M.D., Cook, N., Hargrave, D., Danson, S., Roxburgh, P., Beggs, A.D., Chaturvedi, A., Chesler, L., Sarmiento-Castro, A., Dive, C., Rothwell, D., Gath, J., Halford, S., Krebs, M.G.

Volltext

Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy von Wienke, Judith, Visser, Lindy L., Kholosy, Waleed M., Keller, Kaylee M., Barisa, Marta, Poon, Evon, Munnings-Tomes, Sophie, Himsworth, Courtney, Calton, Elizabeth, Rodriguez, Ana, Bernardi, Ronald, van den Ham, Femke, van Hooff, Sander R., Matser, Yvette A.H., Tas, Michelle L., Langenberg, Karin P.S., Lijnzaad, Philip, Borst, Anne L., Zappa, Elisa, Bergsma, Francisca J., Strijker, Josephine G.M., Verhoeven, Bronte M., Mei, Shenglin, Kramdi, Amira, Restuadi, Restuadi, Sanchez-Bernabeu, Alvaro, Cornel, Annelisa M., Holstege, Frank C.P., Gray, Juliet C., Tytgat, Godelieve A.M., Scheijde-Vermeulen, Marijn A., Wijnen, Marc H.W.A., Dierselhuis, Miranda P., Straathof, Karin, Behjati, Sam, Wu, Wei, Heck, Albert J.R., Koster, Jan, Nierkens, Stefan, Janoueix-Lerosey, Isabelle, de Krijger, Ronald R., Baryawno, Ninib, Chesler, Louis, Anderson, John, Caron, Hubert N., Margaritis, Thanasis, van Noesel, Max M., Molenaar, Jan J.

Volltext

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma von Umapathy, Ganesh, El Wakil, Abeer, Witek, Barbara, Chesler, Louis, Danielson, Laura, Deng, Xianming, Gray, Nathanael S, Johansson, Mikael, Kvarnbrink, Samuel, Ruuth, Kristina, Schönherr, Christina, Palmer, Ruth H, Hallberg, Bengt

Volltext

Metalloproteinase Inhibition and Erythroid Potentiation Are Independent Activities of Tissue Inhibitor of Metalloproteinases-1 von Chesler, Louis, Golde, David W., Bersch, Noelle, Johnson, Mark D.

Volltext

Regulation of oncogenic transcription and tumor growth in pediatric cancers by the CDK9 inhibitor KB-0742 von Saffran, D., Poon, E., Ibanez, G., Nakashima, J., Naffar-Abu Amara, S., Noe, C., Hood, T., Kumar, P., DiMartino, J., Dela Cruz, F., Chesler, L., Lin, C.Y.

Volltext

Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma von Nijhuis, A, Sikka, A, Yogev, O, Herendi, L, Balcells, C, Ma, Y, Poon, E, Valbuena, G, Xu, Y, Liu, Y, Martins da Costa, B, Gruet, M, Wickremesinghe, C, Benito, A, Kramer, H, Montoya, A, Carling, D, Want, E, Jamin, Y, Chesler, L, Keun, H

Volltext

55 - Lactate and choline metabolites are potential biomarkers for monitoring response to mTOR pathway inhibitors in combination with the ALK inhibitor crizotinib in ALK-mutated neu... von Al-Saffar, N.M.S., Jackson, L.E., Sidhu, J., Chesler, L., Leach, M.O.

Volltext

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children... von Moreno, L, Caron, H, Geoerger, B, Eggert, A, Schleiermacher, G, Brock, P, Valteau-Couanet, D, Chesler, L, Schulte, JH, De Preter, K, Molenaar, J, Schramm, A, Eilers, M, Van Maerken, T, Johnsen, JI, Garrett, M, George, SL, Tweddle, DA, Kogner, P, Berthold, F, Koster, J, Barone, G, Tucker, ER, Marshall, L, Herold, R, Sterba, J, Norga, K, Vassal, G, Pearson, ADJ

Volltext

Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse von Vodovotz, Y, Geiser, A G, Chesler, L, Letterio, J J, Campbell, A, Lucia, M S, Sporn, M B, Roberts, A B

Volltext

Abstract B12: The ALK inhibitor PF-06463922 shows significant response as a single agent in ALK/MYCN driven models of neuroblastoma von Guan, J., Danielson, L., Chand, D., Jamin, Y., Ruuth, K., Tucker, E., Umapathy, G., Wakil, A. El, Witek, B., Johnson, T. W., Smeal, T., Chesler, L., Palmer, R. H., Hallberg, B.

Volltext

06.03 Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy von Wienke, J, Visser, LL, Kholosy, WM, Keller, KM, Barisa, M, Munnings-Tomes, S, Carlton, E, Poon, E, Rodriguez, A, Bernardi, R, van den Ham, F, van Hooff, SR, Langenberg, KPS, Holstege, FCP, Chesler, L, Anderson, J, Caron, HN, Margaritis, T, van Noesel, MM, Molenaar, JJ

Volltext

Henoch–Schönlein Purpura With Severe Jejunitis and Minimal Skin Lesions von Chesler, Louis, Hwang, Linda, Patton, Wendy, Heyman, Melvin B

Volltext